// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

What are the best biomarkers of clinical and radiographic features of knee osteoarthritis

Y. Liem - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Chondroitin sulfate

The molecular genetics and epigenetics of COLGALT2, a risk locus for osteoarthritis

Y. Kehayova - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Impaired chondrcoyte U3 SNORNA expression in osteoarthritis and its impact on the chondrocyte's protein translation apparatus

E.G. Ripmeester - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Large-scale genome-wide meta-analyses provide insights for the development of new disease modifying targets for osteoarthritis

K. Hatzikotoulas - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Mendelian randomization identifies a causal role for serum insulin-like growth factor-1 in hip osteoarthritis

A.E. Hartley - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Mecasermin

Disruption of adolescent growth plate dynamics following removal of a putative chondrocyte mechanostat

C.R. Coveney - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tamoxifen

Is the paradoxical increase of cartilage thickness in ctgf null mice due to compensation by activin A

H. Muhammad - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tamoxifen

The ciliary protein intraflagellar transport 88 is required for the maturation, homeostasis and mechanoadaptation of articular cartilage

C.R. Coveney - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tamoxifen

Temporal relationship between osteoarthritis and comorbidities: a combined case control and cohort study in the United Kingdom primary care setting

S. Swain - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Osteoarthritis

N/A

Triggers for acute flares of knee osteoarthritis: a web-based case-crossover study in community-dwelling adults

M.J. Thomas - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study

F. Eckstein - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Sprifermin

Obese synovial fibroblasts exhibit single cell subsets with specific pathological inflammatory functions in osteoarthritis patients

S.N. Wijesinghe - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Synchronising the circadian clock with external stimuli during in vitro chondrogenesis

C. Matta - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Interleukin-17A, -F, and -AF induce expression of pro-inflammatory genes in end-stage osteoarthritis chondrocytes and synovial fibroblasts

J.Y. Mimpen - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

secukinumab

Differences in treating knee osteoarthritis by clinician specialty

D. Baldock - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Methadone hydrochloride

TNF alpha-stimulated gene 6 (TSG6) is chondroprotective in vivo but overexpression cannot compensate for loss of FGF2

L. Zhu - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effect of melanocortin peptides on snap activated chondrocytes

V.C. Can - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Penicillamine

Development of a novel histological scoring system for bone marrow lesions - the osteoarthritis bone score

S. Koushesh - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Identification of putative sex-dependent pain pathways that may explain why female mice devlop pain behaviour despite lower chondropathy scores

V. Batchelor - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Demographic, psychosocial factors, musculoskeletal pain and prescription opioid use in community-based middle-aged women - a prospective cohort study

S. Hussain - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Epimorph

Copyright © 2026. QuantiNova All rights reserved